SARC028

NCT02301039 📎

Regimen

Experimental
Pembrolizumab 200 mg IV Q3W, single-arm
Control
none (single-arm phase 2)

Population

Advanced unresectable or metastatic bone sarcoma (osteosarcoma, Ewing sarcoma, chondrosarcoma, dedifferentiated chondrosarcoma; n=40) and soft-tissue sarcoma (n=40) after prior therapy

Key finding

Pembrolizumab monotherapy essentially inactive in bone sarcoma overall; only dedifferentiated chondrosarcoma showed any meaningful signal. The headline 'IO-in-bone-fails' trial that reset enthusiasm for checkpoint inhibitors in osteosarcoma and Ewing.

Source: PMID 28988646

Timeline

    Guideline citations

    • NCCN BONE (p.31)